Not all chronic myeloid leukemia (CML) patients are cured with tyrosine kinase inhibitors
(TKIs), and a proportion of them develop resistance. Recently, continuous BCR-ABL gene …

The onset of global epigenetic changes in chromatin that drive tumor proliferation and
heterogeneity is a hallmark of many forms of cancer. Identifying the epigenetic mechanisms …

In an inducible oncogenesis model, the miR-200 family is inhibited during CSC formation
but not transformation, and inhibition of miR-200b increases CSC formation. Interestingly …

Background The advanced phases of chronic myeloid leukemia (CML) are known to be
more resistant to therapy. This resistance has been associated with the overexpression of …

Polycomb repressive complex 2 (PRC2) trimethylates lysine 27 of histone H3 (H3K27me3)
to regulate gene expression during diverse biological transitions in development, embryonic …

Genetic studies of Wnt11 have revealed many insights into the roles and regulation of
Wnt11, particularly during development. New tools to study Wnt11 have recently become …

Abstract The Polycomb group (PcG) of proteins is a major mechanism of epigenetic
regulation that has been broadly linked to cancer. This system can repress gene expression …

Leukemia stem cells (LSC) are resistant to conventional chemotherapy and persistent LSC
after chemotherapy are supposed to be a major cause of relapse. However, information on …

Chronic myeloid leukemia (CML) is a hematopoietic stem cell disorder characterized by
BCR-ABL1, an oncogenic fusion gene arising from the Philadelphia chromosome. The …

Chronic myeloid leukemia (CML) is a pluripotent hematopoietic disorder that is currently
considered incurable. The tyrosine kinase product of the Philadelphia chromosome, P210 …